FDA starts building a new path for rare disease treatments
Published
Only about 5% of rare conditions have an approved therapy. The agency wants clearer rules, earlier patient input and approaches suited to tiny trials, and it will hold a public meeting Oct. 28.
Source: HHS
This is a plain-language summary. Read the original source for full details.